Orilanolimab clinical trials
Also written ALXN1830 and SYNT001.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses orilanolimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Studies
Open first, then newest update. How each study uses orilanolimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study of ALXN1830 in Healthy Adult ParticipantsTerminatedPhase 1Alexion Pharmaceuticals, Inc.NCT04730804Written as ALXN1830
- A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult ParticipantsTerminatedPhase 1Alexion Pharmaceuticals, Inc.NCT05254613Written as ALXN1830
- Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic AnemiaWithdrawnPhase 2Alexion Pharmaceuticals, Inc.NCT04956276Written as ALXN1830
- Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia GravisWithdrawnPhase 2Alexion Pharmaceuticals, Inc.NCT04982289Written as ALXN1830
- ALXN1830 in Patients With Warm Autoimmune Hemolytic AnemiaWithdrawnPhase 2Alexion Pharmaceuticals, Inc.NCT04256148Written as ALXN1830
- A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)TerminatedPhase 1/2Alexion Pharmaceuticals, Inc.NCT03075878Written as ALXN1830
- A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)TerminatedPhase 1/2Alexion Pharmaceuticals, Inc.NCT03075904Written as ALXN1830
- A Study of SYNT001 in Healthy VolunteersCompletedEarly Phase 1Syntimmune, Inc.NCT03643627Written as SYNT001
Codes
What other systems call orilanolimab · ClinicalTrials.gg INT001369
- MeSH (NLM) C000708950orilanolimabOne source NLM
- UNII (FDA) 1LTT6HMX9NORILANOLIMABConfirmed FDA, NLM
- NCI Thesaurus C139561OrilanolimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000708950 | orilanolimab | One source NLM |
| UNII (FDA) | 1LTT6HMX9N | ORILANOLIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C139561 | Orilanolimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.